Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of Cerebral Oximetry-Guided Treatment on Brain Injury in Preterm Infants as Assessed by Magnetic Resonance Imaging at Term Equivalent Age: An Ancillary SafeBoosC-III Study.
Alsina-Casanova M, Lühr-Hansen M, Aldecoa-Bilbao V, Del Rio R, Maton P, Sarafidis K, Zafra-Rodriguez P, Vesoulis ZA, Mastretta E, Bresesti I, Gomez-Chiari M, Rebollo M, Khamis J, Baltatzidis A, Benavente-Fernandez I, Shimony J, Morana G, Agosti M, Carreras N, Cuaresma A, Gau A, Anastasiou A, Lubian-López SP, Alexopoulos D, Sciortino P, Dessimone F, Harboe Olsen M, Agut T, Greisen G. Alsina-Casanova M, et al. Among authors: sarafidis k. Neonatology. 2024 Jun 21:1-8. doi: 10.1159/000539175. Online ahead of print. Neonatology. 2024. PMID: 38934161
Detailed statistical analysis plan for a secondary Bayesian analysis of the SafeBoosC-III trial: a multinational, randomised clinical trial assessing treatment guided by cerebral oximetry monitoring versus usual care in extremely preterm infants.
Olsen MH, Hansen ML, Lange T, Gluud C, Thabane L, Greisen G, Jakobsen JC; SafeBoosC-III Trial Group. Olsen MH, et al. Trials. 2023 Nov 16;24(1):737. doi: 10.1186/s13063-023-07720-3. Trials. 2023. PMID: 37974280 Free PMC article. Clinical Trial.
Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial.
Hill LF, Clements MN, Turner MA, Donà D, Lutsar I, Jacqz-Aigrain E, Heath PT, Roilides E, Rawcliffe L, Alonso-Diaz C, Baraldi E, Dotta A, Ilmoja ML, Mahaveer A, Metsvaht T, Mitsiakos G, Papaevangelou V, Sarafidis K, Walker AS, Sharland M; NeoVanc Consortium. Hill LF, et al. Among authors: sarafidis k. Lancet Child Adolesc Health. 2022 Jan;6(1):49-59. doi: 10.1016/S2352-4642(21)00305-9. Epub 2021 Nov 26. Lancet Child Adolesc Health. 2022. PMID: 34843669 Free PMC article. Clinical Trial.
97 results